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Breast organ doses, effective doses and lifetime attributable risk (LAR) of breast cancer from chest CT scans are presented for
200 female patients surveyed from 10 hospitals in the West Bank and Gaza Strip, Palestine. Patient data were collected and
organized in a database from May to November 2016. Data include age (15–80 years), weight, height, and calculated body mass
index. Exposure data were also recorded for every examination. Exposure data includes milliampere-second (mAs), X-ray tube
kilovoltage (kVp), computed tomography dose index, dose length product, manufacturer, name and type of operated CT scanner.
Organ and effective doses were evaluated using a web-based commercially available Monte Carlo software: VirtualDose™CT, a
product of Virtual Phantoms, Inc. The software utilizes male and female tissue equivalent phantoms of all ages and sizes including
pregnant patients. The corresponding phantom was selected for every patient according to patient’s tomographic parameters.
Calculated organ doses were used to estimate the LAR of breast cancer according to BEIR VII Phase 2 report. It was found that
radiation doses resulting from the same exam vary widely between different hospitals, depending on the parameters used and the
type of scanner. For all patients, the breast organ dose ranged from 6.5 to 28mGy per examination, with an average breast organ
dose of 15mGy. The effective dose from chest CT scan per examination ranged from 3 to 14.7mSv with an average of 7 mSv.
For younger females (15–29 years), the LAR of breast cancer risk was estimated to be around 0.05%. For older female patients
(60–79 years), the risk was ~0.001%. It was found that LAR decreases remarkably with patient’s age. Values obtained in this
study vary between hospitals, they are generally low and consistent with other studies reported worldwide.
INTRODUCTION
The computed tomography (CT) imaging plays a
necessary role in modern medicine. CT scan is espe-
cially useful because it can simultaneously show many
different types of tissue including the lungs, heart,
bones, soft tissues, muscle and blood vessels. This
medical diagnosis modality delivers radiation doses to
patients higher than those from conventional medical
imaging. CT scans account for ~20% of the total
medical X-ray procedures performed worldwide. This
high-dose procedure however contributes ~43% of the
annual collective dose from all medical X-ray exami-
nations to the population(1, 2). Its rapid adoption has
resulted in a dramatic increase in the average medical
radiation exposure. For example, a chest CT scan typ-
ically delivers more than 100 times the radiation dose
of a routine frontal and lateral chest radiograph.
Furthermore, radiation exposure from CT examina-
tions has also increased, in part due to the increased
speed of image acquisition allowing vascular, cardiac
and multiphase examinations, which are associated
with higher doses(3). Lack of optimized protocols
could be an additional source of increased radiation
dose to patients. It is also very important to keep the
radiation dose as low as reasonably achievable. The
optimization of radiation dose is a legal requirement
in medical exposure(4).
Patients have beneﬁted from the rapid diagnoses
made possible by CT scan and from its value for
monitoring chronic disease. However, there is an
increasing concern regarding the risks of such radi-
ation exposure. The typical estimated dose asso-
ciated with proper use of CT scan is in the range of
2–10mSv in which the deterministic effects are not
normally a concern. Induction of cancer by radi-
ation is a probabilistic (stochastic) effect. That is,
higher radiation doses are associated with a higher
likelihood of carcinogenesis, but even low doses of
radiation could potentially induce carcinogenesis(5).
Major international organizations share the belief
that the risk of developing cancer in patients exposed
to radiation from CT scans is very low but appears
to be more than hypothetical(6). The ICRP Special
Task Force 2000 reported that the doses from CT
often approach or exceed levels that are known to
increase the probability of nonfatal and fatal can-
cers(7). Because this topic has recently attracted the
attention of both the scientiﬁc community and the
general public, it has become increasingly important
for physicians to understand the cancer risk asso-
ciated with CT scans(8).
The breast tissue of young women is one of the
most radiation sensitive tissues in a human body. The
sensitivity of breast tissue has been demonstrated in
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the Japanese atomic bomb survivors(9). A signiﬁcant
increased risk in the incidence of breast carcinoma has
been demonstrated in patients who have received sub-
stantial cumulative doses to the breast from multiple
diagnostic x-ray procedures and from radiation therapy
for benign diseases. It has been reported that the deliv-
ery of 0.01Gy to a woman younger than 35 years can
increase the lifetime risk of breast cancer by 13.6%(10).
The breast weighting factor was increased to 0.12 from
0.05 as reported in ICRP publication 60 and ICRP
publication 103(11, 12). This is due to recent research
showing the increased radiation sensitivity of breast tis-
sue and the fact that breast cancer accounts for about
one quarter of the total detriments in females(13).
The radiation dose to particular organs from any
given CT scan depends upon a number of factors: the
most important are the number of scans, mAs, patient
size, axial scan range, scan pitch (the degree of over-
lap between adjacent CT slices), maximum kVp and
the particular scanner design(14). In addition, there are
some factors that have an indirect effect on radiation
dose. For example, choice of image reconstruction ﬁl-
ter affects noise level and image quality, which could
drive an operator to change exposure settings, and
therefore affecting the radiation dose(15).
Several methods have been described in the litera-
ture on the assessment of effective from CT examina-
tions. The most direct way of estimating doses to
patients undergoing CT examinations is to measure
organ doses in patient-like phantoms using dose
length product (DLP) and body region-speciﬁc coef-
ﬁcients. These coefﬁcients are published values of
(effective dose)/DLP that can be used to convert cal-
culated values of DLP into patient effective dose(16).
Another way of obtaining the pattern of energy
deposition in patients undergoing CT examinations
is by Monte Carlo calculations(17). Patient and
scanner-speciﬁc Monte Carlo simulations have been
used to accurately estimate radiation dose from CT
examinations(18). To calculate patient effective and
organ doses, normalized dose data based on simula-
tion measurements published in the literature can
also be used(19, 20). Because the use of the effective
dose is not recommended for the evaluation of sex-
speciﬁc risks and because of the importance of the
patient’s age at the time of exposure in terms of
breast cancer risk and other solid cancer induction
risks, BEIR VII risk estimates are used to estimate
the risks of radiation-induced cancer incidence and mor-
tality from breast imaging studies rather than ICRP
effective dose methods(21).
Although not intended for individual patient dose
assessment, effective dose can be used for comparison
and summation of dose from different modalities(22).
Such relative comparisons can be used for both gen-
eric justiﬁcation and optimization of medical expo-
sures, but not to predict absolute risk levels. Values
have been derived for a variety of diagnostic procedures
in radiology and nuclear medicine in order to provide
a relative index of harm that can be considered for jus-
tiﬁcation of medical exposures(23).
Currently, there are ~28 CT scanners in Palestine,
24 in the West Bank and 4 in Gaza Strip. CT scans
account for ~20% of the total medical X-ray proce-
dures performed in the country, and chest CT scan is
one of the most frequently requested procedures. There
are no local studies concerning risk evaluation from
radiation exposure in CT. This work aims at the asses-
sing breast organ doses, effective doses and quantifying
the radiation risk of breast cancer incidence during
chest CT examinations performed on 200 female
patients randomly selected from 10 Palestinian hospi-
tals in the West Bank and Gaza Strip.
MATERIALS AND METHODS
Assessment of organ and effective doses was performed
theoretically using commercially available web-based
Monte Carlo simulation software: VirtualDoseTM
developed by Virtual Phantoms, Inc, New York. The
software is based on a comprehensive database of
organ doses derived from MC simulations involving
a library of 25 anatomically realistic phantoms that
represent patients of different ages, body sizes and
masses, and pregnancy stages(24). VirtualDose enables
users to assess organ doses, in addition to the CTDI
and DLP data provided by each CT scanner. A com-
prehensive library of patient models covers both males
and females of various ages and body weights. It is
ready for use with the latest CT scanners and utilizes
both ICRP-60 and ICRP-103 standards on effective
dose(25).
Lifetime attributable risk (LAR) of breast cancer
incidence was estimated from absorbed organ doses
using age speciﬁc cancer risk models in the biological
effects of ionizing radiations (BEIR) VII Phase 2
report. For each patient age, the estimated LAR of
cancer incidence from 100mSv organ equivalent dose
was determined using tabulated risk values of the
BEIRVII report. If data were not available for a spe-
ciﬁc age, then linear interpolation was performed
from the nearest two tabulated ages(26, 27).
Demographic data for 200 female patients were
collected in order to maintain consistency of the
information displayed during CT scan examinations.
Patient data includes age, height, weight and body
mass index (BMI). The age, weight and height of
patients ranged from 15 to 80 years, 50 to 110 kg
and 150 to 185 cm, respectively. BMI was calculated
from the average weights and heights for each hos-
pital according to the equation BMI = weight/
(height in meter)2. Calculated average body mass
indices for the 10 hospitals ranged from 25.28 to 30.
The average x-ray tube voltage used in all scanners
was 120 kVp. Table 1 presents the number of
patients, average BMI, scanner speciﬁcations and
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exposure related parameters for all surveyed hospi-
tals. All scanner protocols utilized ﬁxed mAs values.
The automatic tube current modulation feature was
not used in any of scans included in the study.
For the calculation of breast organ absorbed dose
and total effective doses, VirtualDose requires the
following input data: virtual patient, scanner type,
scan protocol, kVp, mAs, pitch, bow tie ﬁlter type
(head or body), beam collimation (mm), Z-over
beaming length (mm) if available, the weighted com-
puted topography dose index (CTDIw), and organ
weighting scheme (whether ICRP 60 or ICRP 103).
These parameters were recorded for every patient
based on her demographic data. Patient’s virtual
phantoms were selected according to International
Classiﬁcation of Adult Underweight and Obesity
according to BMI(28) speciﬁc dose metrics (radiation
dose indicators). Additionally, DLP and CT volume
dose index (CTDIvol) were recorded for every patient
and every CT scan. They were obtained from a dose
summary page, which appears on each CT scanner
monitor and includes information about the CT scan
examination. CTDIvol allows the comparison of scan
protocols or scanners and is useful for obtaining
data to compare techniques. DLP is an indicator of
the dose imparted to the patient and is estimated by
multiplying CTDIvol and scan length. In addition to
being affected by the issues associated with CTDIvol,
DLP can be problematic in a limited scan range. CT
scanners record the radiation exposure as a DLP in
mGy cm. DLP can be multiplied by the appropriate
conversion factor to calculate the effective dose in
mSv. The dose length is typically saved on picture
archiving and communication system (PACS) within
a radiation report that appears as a separate series
in the form of a screenshot(29). CTDIw was calcu-
lated as CTDIw = CTDIvol × pitch. For every patient
undergoing chest CT scan, VirtualDose calculates
organ doses and total effective dose. Table 2 presents
the average values of dose metrics for all surveyed hos-
pitals. It also shows average values of CTDIvol, DLP
and pitch for patient during chest CT scan in each
hospital.
RESULTS AND DISCUSSION
There are wide variations in patient CT dose indica-
tors among investigated hospitals. Variations in DLP
and CTDIvol for chest CT examination were
410–1067mGy cm and 3.75–16.6 mGy, respectively.
Additionally, mAs varied widely from 168 to 350,
whereas kVp values were the same for all scanners.
The variation of mAs per given examination could
be expected due to the difference in patient demo-
graphics and number of detectors raws for each scan-
ner. A low detector raw number CT scanner could
result in higher patient dose due to shorter volume
coverage and slower rotation times. It takes more









H1 10 26.5 Philips Brilliance iCT BIG Bore, 128 slices 570 200 4
H2 15 25.4 Philips Brilliance iCT BIG Bore, 128 slices 570 200 4
H3 15 27.4 Philips Brilliance iCT BIG Bore, 128 slices 570 216 6
H4 30 28 Philips Brilliance 16 slices 570 300 20
H5 30 25.3 Siemens SOMATOM AS + 128 slices 595 168 4
H6 20 26 Philips Brilliance 64 channel with Essence
technology
570 200 6
H7 20 27 Siemens SOMATOM Emotion 16 slices 535 240 20
H8 20 30 Philips Brilliance 16 slices 570 250 21
H9 20 26.6 Philips Brilliance iCT BIG Bore, 128 slices 570 200 8
H10 20 27 Philips Brilliance 16 slices 570 350 21
BMI, body mass index; FID, focus isocenter distance.








H1 6 6 1 423
H2 8 8 1 410
H3 7.7 7.7 1 410
H4 11 10 0.9 978
H5 5.6 5 0.9 427
H6 6 6 1 406
H7 8 7 0.9 967
H8 15 13.5 0.9 1000
H9 3.75 3.75 1 407
H10 16.6 14.8 0.9 1067
CTDIw = CTDIvol × pitch; DLP = CTDIvol × scan length.
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time to cover anatomical parts, which is expected to
result in higher radiation dose. Other indicators such
as pitch and scan time also affect the amount of
radiation dose delivered. It is interesting that mAs
varied by a factor of 1.45 between hospitals H8 and
H10, both of which employ the same CT scanner
(16-raw number, pitch, scan time and BMI). This
might indicate that scanning protocols are not stan-
dardized between hospitals.
The breast organ dose for all patients ranges from
6.5 to 28mGy, with an average dose of 15 mGy.
Variation of organ dose between individual hospitals
are relatively high reaching a factor up to 4.3. In a
work published by Angel et al.30, they reported
breast organ doses from chest CT scans in the range
from 14 to 29mGy with a mean of 19 mGy. Figure 1
presents the average organ doses obtained in this
study for all investigated hospitals.
The values of calculated effective doses for all hos-
pitals are also widely distributed between hospitals
ranging from 3mSv average value for H9 and
14.7 mSv average value for H8. The total average of
effective dose for all investigated patients is 7 mSv.
Figure 2 shows the average values of effective doses
from all hospitals. Table 3 presents a comparison
between effective doses received in this work and
published in the literature.
These variations are related to the utilized proto-
cols as well as the different methods used for the esti-
mation of the organ dose
The tendency for variations in organ and effective
doses for the same examination are seen similar for
all investigated hospitals with H4 and H8 having the
highest doses delivered to patients as it is the case of
DLP and CTDIvol. H5 and H9 have the lowest
organ and effective doses. Again, these differences
could be explained due to different scanner type,
mAs, scan time and also BMI, which is high in the
cases of H4 and H8, whereas H5 and H9 had low
BMI values. Although the doses used in CT are
higher than those used in conventional radiographic
examinations, they are still 10–100 times lower than
the dose levels that have been reported to increase
the risk of cancer(35).
Although effective dose best reﬂects a patient’s
overall exposure to radiation, organ-speciﬁc dose
may be more appropriate for estimating lifetime can-
cer risk for nonuniform exposures such as CT. For
example, if a patient undergoes an imaging study
that only irradiates the breast, her risk of cancer from
that examination will primarily reﬂect her increased
risk of breast cancer(36).
Calculated breast absorbed doses were used for risk
assessment of medical radiation exposure that can
induce cancer according to the Committee on the
Biological Effects of Ionizing Radiations Phase 2 mod-
eling (BEIR VII Phase 2). The BEIR VII has been
derived by lifetime risk estimates for cancer incidence
and mortality resulting from a single dose of 0.1Gy at
several speciﬁc ages. Estimates are shown for all cancer,
leukemia, breast, all solid cancer and cancer of several
speciﬁc sites. For each patient, the estimated LAR of
cancer incidence from 100mSv organ equivalent dose
was determined using the table published in BEIRVII
report for lifetime attributable breast cancer risk of
incidence. If data were not available for a speciﬁc age,
a linear interpolation was performed from the nearest
two tabulated ages. This LAR from a theoretical
100mSv organ dose was scaled linearly based on the
Figure 1. Average breast organ doses for all hospitals. Figure 2. Average effective doses received by patients from
different hospitals.
Table 3. Estimated effective doses from chest CT
examinations of the adult female patient compared with
reported values in the literature(31–34).
Work Effective dose (mSv)
Range (mSv) Average (mSv)
This work 3–14.7 7
Tsai et al. 3.8–9.2 5.6
Origgi et al. 2.8–16 7.9
Aldrich et al. 3.8–26 9.3
Osei et al. 3.6–13.8 7.9
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actual organ dose determined in the Monte Carlo
simulation. For example, the breast equivalent dose for
a 50-year-old woman from a standard chest CT scan is
12mSv; the LAR of breast cancer incidence for this
woman from a 100mSv Breast dose is 70 cases per
100 000 according to the BEIRVII preferred model, so
the LAR from a 12mSv dose is (12/100) × (70/
100 000) or 0.008% or 100 000/(12/100) × 70 = 1 in
6803. The normalized Lifetime attributable breast can-




nLAR % Breast organ dose
100 mSv




This method of LAR calculation is consistent with
the concept of ‘Effective risk’ suggested by Brenner
in 2008. According to Brenner and Huda37, the
whole-body effective risk of cancer incidence R is
deﬁned as follows:
∑= ( )τ τR r H 2
where R is the whole-body cancer risk, τr is the life-
time tissue-speciﬁc cancer risk (per unit equivalent
dose to tissue T) and τH is the tissue-speciﬁc equiva-
lent dose for tissue T.
Figure 3 shows the average LAR of breast cancer
incidence for all investigated hospitals.
Figure 4 shows the LAR of breast cancer incidence
as a function of age for 26 female patients undergoing
chest CT scan in hospital H5. Table 4 presents the
mean LAR for breast cancer incidence for different
age groups from all investigated hospitals.
Table 4 presents the lifetime attributable breast
cancer risk for different age groups. The LAR
decreases with age as also indicated in Figure 4.
Radiosensitivity of many organs such as the breast has
been observed to decrease with age(38). Moreover, a long
lag time is typical from acute radiation exposure to the
development of malignancy, e.g. a 12-year minimum
latency period from radiation exposure to excess breast
cancer risk has been described in Japanese atomic bomb
survivors(39). Consistent with this, older patients in this
study who were both less radiosensitive and less likely to
survive to the development of a radiation-attributable
cancer, had lower LARs than younger patients.
CONCLUSION
This work has discussed the radiation doses and asso-
ciated breast organ cancer risk to female patient under-
going chest CT scan in 10 hospitals from the West
Bank and Gaza Strip. Obtained dose values and risks
are variable from hospital to hospital depending on the
used protocols and techniques for chest CT scans.
Variations between hospitals as well as average values
of breast organ and effective doses are comparable
with values reported in literature. This, however, raise
the need for responsible national authorities to opti-
mize CT scanning protocols for the same examinations
to reduce the patient’s dose as low as reasonably
achievable. The radiation doses and associated risks of
breast cancer incidence from chest CT scan are gener-
ally low and the beneﬁts of using CT technology
makes it indispensable in medical imaging of the chest.
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